Am J Med Genet B Neuropsychiatr Genet

1. VEREBI C, Louveau C, Diebold B, Gaitch N, et al
   Extending the ATP9A-Related Phenotypic Spectrum: Indication of Schizophrenia Susceptibility.
   Am J Med Genet B Neuropsychiatr Genet. 2026 Sep 18. doi: 10.1002/ajmg.b.70036.
   

   >> Share

   
   

   
   Br J Psychiatry

2. KENNY EA, Brand BA, Ebrahimi OV, McCutcheon RA, et al
   Dopamine antagonists and dynamic symptom networks in schizophrenia.
   Br J Psychiatry. 2026 Sep 14:1-7. doi: 10.1192/bjp.2026.10775.
   

   >> Share

   
   

   
   Can J Psychiatry

3. LIU JCW, Gorbovskaya I, Zhang AY, Hahn MK, et al
   Investigation of the Gut Microbiome in Treatment-Resistant Schizophrenia Compared to Healthy Controls: A Cross-Sectional Pilot Study: Etude du microbiome intestinal chez les patients atteints de schizophrenie resistante au traitement par rapport aux t
   Can J Psychiatry. 2026 Sep 18:7067437261487782. doi: 10.1177/07067437261487782.
   

   >> Share

   
   

   
   J Clin Psychiatry

4. CHEN Y, Hu L, Meyer JM, Citrome L, et al
   Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder.
   J Clin Psychiatry. 2026;87:26m16416.
   

   >> Share

   
   

   
   Mol Psychiatry

5. SU Q, Li M, Qiu Y, Sun X, et al
   The genetic overlap between schizophrenia and major depression with cognitive function.
   Mol Psychiatry. 2026 Sep 16. doi: 10.1038/s41380-026-03887.
   

   >> Share

   
   
6. JI YS, Liu YF, Mu ZQ, Fang-Fang L, et al
   Prevalent and characteristic alterations in blood-brain transcriptomic-functional imaging coupling in schizophrenia.
   Mol Psychiatry. 2026 Sep 14. doi: 10.1038/s41380-026-03873.
   

   >> Share

   
   

   
   Nat Ment Health

7. HYATT AS, Flores MW, Overhage L, Bien-Aime D, et al
   Emergency department use by individuals with and without psychosis after state-level cannabis legalization and commercialization.
   Nat Ment Health. 2026;4:1122-1129.
   

   >> Share

   
   

   
   Neuropsychopharmacology

8. THEIS N, Rubin J, O'Rourke E, Bahuguna J, et al
   Temporal stability of functional network configurations and its relationship to cognition and psychopathology in early psychoses.
   Neuropsychopharmacology. 2026 Sep 12. doi: 10.1038/s41386-026-02544.
   

   >> Share

   
   

   
   Proc Natl Acad Sci U S A

9. TRIPATHI SJ, Chakraborty S, Wood NB, Hoopes D, et al
   Catechol-O-methyltransferase connects dopamine homeostasis to redox signaling, metal homeostasis, and protein folding in schizophrenia.
   Proc Natl Acad Sci U S A. 2026;123:e2606205123.
   

   >> Share

   
   

   
   Psychiatry Res

10. WU Y, Ma J, Zhang Y, Zhang L, et al
    Network analysis of depressive and anxiety symptoms in schizophrenia: Revealing central symptoms and suicide risk.
    Psychiatry Res. 2026;366:117462.
    

    >> Share

    
    
11. FRANZENBURG KR, Hansen R, Suett M, Yaari A, et al
    Factors associated with rates of long-acting injectable antipsychotic use for schizophrenia: A subgroup analysis of the multinational ADVANCE study.
    Psychiatry Res. 2026;366:117452.
    

    >> Share

    
    
12. FORTE MF, Rabelo-da-Ponte FD, Clougher D, Segura AG, et al
    Cognitive profiles in first-episode psychosis: The impact of genetics, environment, and cognitive reserve as risk and protective factors.
    Psychiatry Res. 2026;366:117428.
    

    >> Share

    
    

    
    Psychol Med

13. GUO Y, Wang W, Li L, Lu X, et al
    Recent stressful life events, immunometabolic markers, and risk of schizophrenia: A prospective cohort study.
    Psychol Med. 2026;56:e273.
    

    >> Share

    
    
14. JELSMA A, de With J, van der Pluijm M, de Koning M, et al
    The role of self-disturbance phenomena and negative-self schemas in the relationship between childhood trauma and psychotic experiences in patients with psychosis, unaffected siblings and healthy controls.
    Psychol Med. 2026;56:e275.
    

    >> Share

    
    
15. CASELANI E, Carnevale M, Zarbo C, Martinelli A, et al
    Bayesian network analysis uncovers physical activity-mood dynamics: Insights from the DiAPAson study.
    Psychol Med. 2026;56:e271.
    

    >> Share

    
    
16. CHU NWT, Chu RST, Fung CCS, Fung VSC, et al
    Early-stage trajectories of social-occupational functioning and long-term functional outcome prediction in early psychosis: A 12-year follow-up of the randomized controlled trial on extended early intervention.
    Psychol Med. 2026;56:e276.
    

    >> Share

    
    

    
    Schizophr Res

17. MANZONI D, Benner JF, Velthorst E, Crafa D, et al
    The role of negativity bias and facial affect recognition in the increased odds of first-episode psychosis in ethnic minority populations: Findings from the EU-GEI case-control study.
    Schizophr Res. 2026;297:525-534.
    

    >> Share

    
    
18. SHIMADA T, Yamanushi A, Tanaka S, Kobayashi M, et al
    Exercise interventions for cognitive impairment in schizophrenia: An umbrella review.
    Schizophr Res. 2026;297:522-524.
    

    >> Share

    
    
19. MYERS AW, Bertrand CE, Mittal VA
    Risk of ketamine exposure in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2026;297:520-521.
    

    >> Share

    
    
20. CHATZISOFRONIOU G, Cohen A
    From AI hallucinations to psychosis: Representational entanglement as a computational bridge.
    Schizophr Res. 2026;297:518-519.
    

    >> Share

    
    
21. LOSHIN J, Culbreth A, Stein A, Joncas E, et al
    Transdiagnostic symptoms and the masking of neurocognitive impairment across the early stages of psychosis.
    Schizophr Res. 2026;297:499-508.
    

    >> Share

    
    
22. TAYLOR CE, Mulligan LD
    Sleep quality and quality of life in people with non-affective psychosis: A systematic review of relationships across phases and age groups.
    Schizophr Res. 2026;297:486-498.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share